The present invention relates to a stent having a functional material coated on a cell space (safe coating space) thereof. The stent of the present invention, as a stent having a space for mounting and coating drugs and other materials for expanding the functions of the stent, is highly feasible as an actual product in consideration of the structure, transfer device, and manufacturing process of the stent as a whole, and secures a coating space (safe coating space) of a functional material in a cell of the stent through quantitative and qualitative modelling. Since an additional increase in volume does not occur even when the stent is press-mounted in a transfer device as a result of mounting a radio marker or a drug in the coating space, the stent of the present invention has excellent radio opacity without obstructing the loading and deployment of the stent, and may stably mount a great amount of a functional drug.

A medication impregnated bone cement (MIBC) coated intramedullary (IM) nail for fixation of a long bone fracture comprising an IM nail base and medication impregnated bone cement. The bone cement encapsulates at least a portion of the IM nail base and forms an interface between the adjacent surfaces of the IM nail base and the bone cement. The interface between the encapsulating bone cement and the encapsulated IM nail base being enhanced to increase the adhesion of the encapsulating bone cement to the encapsulated IM nail base. The increase in adhesion being sufficient to ensure that the encapsulating bone cement remains adhered to the encapsulated IM nail base when the medication impregnated bone cement coated intramedullary nail is removed from the long bone.

A medication impregnated bone cement (MIBC) coated intramedullary (IM) nail for fixation of a long bone fracture comprising an IM nail base and medication impregnated bone cement. The bone cement encapsulates at least a portion of the IM nail base and forms an interface between the adjacent surfaces of the IM nail base and the bone cement. The interface between the encapsulating bone cement and the encapsulated IM nail base being enhanced to increase the adhesion of the encapsulating bone cement to the encapsulated IM nail base. The increase in adhesion being sufficient to ensure that the encapsulating bone cement remains adhered to the encapsulated IM nail base when the medication impregnated bone cement coated intramedullary nail is removed from the long bone.

Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

Disclosed herein are compositions to use in biofouling-resistant coatings, biofouling-resistant coatings, methods of making biofouling-resistant coatings, biofouling-resistant devices, and methods of making biofouling-resistant devices.

Disclosed herein are compositions to use in biofouling-resistant coatings, biofouling-resistant coatings, methods of making biofouling-resistant coatings, biofouling-resistant devices, and methods of making biofouling-resistant devices.

A drug-loaded implanted medical device (10) and a preparation method therefor. The drug-loaded implanted medical device (10) comprises a device body (100), a hydrophilic coating layer (200) loaded on the device body (100), and crystalline drug particles (300) loaded on the hydrophilic coating layer (200). The hydrophilic coating layer (200) comprises a graft polymer containing a photo-crosslinked group. The medical device (10) uses a hydrophilic coating layer (200) as a carrier, effectively avoiding the risk of embolism, encouraging the crystalline drug particles to fall off, and helping to achieve a target tissue concentration. The invention can also effectively increase the anchoring effect between the carrier and the device, and reduce toxicity.

Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.

Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.